Pediatric Cystic Fibrosis Clinical Trials

Current Pediatric Cystic Fibrosis Clinical Trials

Study title: TIDES 2.0: Prevalence and Longitudinal Course of Depression, Anxiety, and Behavior Problems in Children With Cystic Fibrosis Under 12 Years of Age

This is a longitudinal, observational epidemiological study designed to estimate the prevalence of depression, anxiety, and behavior problems in children ages 18 months through 11 years with cystic fibrosis (CF).

NCT Number: NCT07048574

Study: STOP360-IP-22 AG

Study title: Standardizing Treatments for Pulmonary Exacerbations: A Platform for Evaluating Treatment Decisions to Improve Outcomes (STOP360) Aminoglycoside Study (AG Study)

To look at pulmonary exacerbations in people with cystic fibrosis (CF) that need to be treated with antibiotics given through a tube inserted into a vein (intravenous or IV). This study is trying to answer the following questions about treating a pulmonary exacerbation:

Do participants have the same improvement in lung function and symptoms if they are treated with one type of antibiotic (called beta-lactams or β-lactams) versus taking two different types of antibiotics (tobramycin and β-lactams)? Is taking one type of antibiotic just as good as taking two types?

NCT Number: NCT05548283